Study of MP0112 Intravitreal Injection in Patients With Wet Age Related Macular Degeneration: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Study of MP0112 Intravitreal Injection in Patients With Wet Age Related Macular Degeneration (NCT01086761), a randomized phase 1 study. The primary outcome is Maximal Tolerated Dose (MTD) Following a Single Injection.

2. Clinical Question

3. Trial Design

This was a phase I, open-label, non-controlled, multicentre clinical trial of intravitreal MP0112 in patients with wet age-related macular degeneration. The record describes a single-group model and a dose-escalation approach. The intervention descriptions specify a single injection in the study eye at each listed dose: 0.04 mg, 0.15 mg, 0.4 mg, 1.0 mg, 2.0 mg, or 3.6 mg. The registry record does not explain the sequence or operational rules for escalation.

The allocation field is recorded as randomized, while the study description says non-controlled and the model is single group. No comparator arm is described for the primary outcome, and the registry record does not clarify what was randomized, how participants were assigned to dose levels, or whether randomization governed any other aspect of the study. These labels should therefore be reported as they appear rather than reconciled by inference.

The recorded enrollment is 32. The study start is listed as 2010-03 and primary completion as 2010-11. Its status is terminated; the registry record does not state why it was terminated. The sponsor is Allergan. The stated purpose was to assess safety and tolerability, with preliminary efficacy and pharmacokinetics also named in the official study description.

The primary outcome was maximal tolerated dose following a single injection, measured in mg over 16 weeks. Secondary outcomes covered stable or improved best corrected visual acuity, retinal thickness, angiographic leakage and lesion area, serum concentration, and binding antibodies. Numerical results for these outcomes are not reported in the registry record. The adverse-event listing covers dose groups through 2.0 mg; it does not give a corresponding group entry for 3.6 mg.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Overall Study

Analysis population for the primary outcome, as defined in the registry: All treated participants.

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as Maximal Tolerated Dose (MTD) Following a Single Injection, measured over 16 weeks.

The primary endpoint is maximal tolerated dose following a single injection, expressed in mg and assessed over 16 weeks. It is a dose-selection endpoint rather than a direct estimate of visual benefit. The registry defines it as one dose level below the lower of two toxicity thresholds: the dose level at which a severe, sight-threatening drug-related adverse event occurred, or the dose level at which more than 2 patients experienced moderate ocular drug-related toxicity. The population for this measure is described as all treated participants.

This type of endpoint is used in early-phase dose-escalation research to identify a dose boundary based on observed tolerability. The definition makes safety events central to the selection rule and specifies a conservative step below the lower toxicity threshold. It does not itself summarize how often participants experienced each event, establish the precision of the dose estimate, or measure efficacy.

The registry record does not report the resulting maximal tolerated dose or the dose-specific toxicity findings needed to verify how the rule was applied. The serious-event listings alone do not provide all information required by the definition: they do not identify whether an event was judged drug-related or sight-threatening, and they do not supply moderate ocular toxicity counts for each dose. Consequently, the endpoint’s definition is available, but its numerical result and the evidence supporting that result are not reported in the registry record.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

The registry record names a primary endpoint and describes how it was to be determined, but it does not report a statistical analysis plan or numerical endpoint result. The explanations below distinguish general statistical concepts in the registry record reported for this trial.

What does a dose-escalation endpoint do?

In general, a dose-escalation study evaluates doses in a planned sequence and uses observed tolerability to guide dose selection. A maximal tolerated dose rule turns toxicity observations into a decision criterion. Here, the record defines the selected dose as one level below the lower of the dose with a severe sight-threatening drug-related adverse event or the dose at which more than 2 patients had moderate ocular drug-related toxicity. This rule is part of the endpoint definition; it does not reveal which dose met either threshold.

Applying such a rule depends on event classification, dose assignment, observation, and the handling of participants who do not complete follow-up. The registry record does not give the detailed escalation procedure, event-adjudication process, or an account of how incomplete observations affected the endpoint. It also does not state whether any additional safety criteria were used.

Why is a comparator important?

In general, a controlled comparison helps separate changes associated with an intervention from changes that may occur over time or for other reasons. This study is described as non-controlled and single-group, so the primary endpoint is framed around dose-specific tolerability rather than a contrast with another treatment or placebo. The record’s allocation label says randomized, but it does not explain the role of randomization. No comparative estimate for the primary outcome is reported.

Without a comparator, event counts can describe what was recorded among participants in the study, but they cannot by themselves quantify excess risk relative to an untreated or alternative-treatment group. They also cannot distinguish drug effects from underlying disease, procedures, or other causes. This is a general limitation of interpretation for uncontrolled data, not a claim about the cause of any event in this trial.

What does a confidence interval contribute?

In general, a confidence interval expresses the range of values compatible with an estimate under the assumptions of the analysis. It helps readers assess precision, whereas a single estimate alone does not show how uncertain that estimate is. The registry record does not report a confidence interval for maximal tolerated dose or for the listed secondary outcomes. Because the primary endpoint is a dose-selection decision, an interval would not replace the endpoint rule, but uncertainty and the underlying dose-specific observations would still help readers judge how stable the selection might be.

How should event counts be understood?

In general, counts and denominators describe how many participants with available event information were affected within a specified group. A denominator may vary across outcomes because eligibility, follow-up, or reporting differs. The serious-event counts in this record are grouped by dose and accompanied by participants at risk. They are descriptive entries; the registry does not provide a model-based comparison or an explanation of whether the counts represent unique people, recurrent events, or adjudicated events beyond the group-level measure. No totals across dose groups should be inferred from these listings.

Seriousness and causality are different classifications. An event can be serious without being judged related to treatment, and a drug-related event need not meet a serious-event definition. The primary endpoint specifically uses severe sight-threatening drug-related events and moderate ocular drug-related toxicity. The serious-event listing alone does not identify those endpoint categories, so it cannot be used as a substitute for the dose-specific toxicity data required by the endpoint rule.

What can secondary outcomes add?

In general, secondary outcomes can describe additional aspects of safety, visual function, anatomy, pharmacokinetics, and immunogenicity. Their interpretation depends on outcome definitions, measurement timing, analysis populations, and methods for handling missing observations. This record names the outcome domains and reports no analysis results for them. It therefore does not support conclusions about the direction, magnitude, variability, or precision of any changes.

Statistical methods for the secondary outcomes, including any adjustment for baseline values or repeated measurements, are not reported in the registry record. The same is true of any formal approach to comparing dose levels. As a result, readers should not assume that unadjusted differences, trends across doses, or tests of significance were part of the sponsor’s analysis.

What does a planning calculation mean?

In general, a sample-size planning illustration asks how many participants might be needed under stated assumptions to detect a specified effect with a chosen significance level and power. Such an illustration is prospective and assumption-dependent. It is not evidence about the probability that an already completed study detected an effect, and it is not “observed power.” The trial record does not report its own sample-size justification or statistical design assumptions, so any separate planning illustration should not be mistaken for the trial’s original plan or for an observed result.

10. Multiplicity, Missing Data and Analysis Populations

The registry lists several secondary outcomes covering visual acuity, retinal thickness, angiographic leakage and lesion area, serum concentration, and binding antibodies. It does not report how many statistical tests were planned, whether outcomes were prioritized beyond the stated primary endpoint, or whether any adjustment for multiple comparisons was intended. The number of outcome measures in a record does not establish how many analyses were performed or how multiplicity was handled.

In general, testing many outcomes can increase the chance that at least one apparently notable result arises by chance. Statistical approaches to address multiplicity can include defining a testing hierarchy or adjusting the threshold for interpretation. No such approach is reported in the registry record. Since numerical results and analysis details for the secondary outcomes are also not reported, readers cannot determine whether any findings were exploratory, confirmatory, or adjusted for multiple testing.

The record does not describe missing-data methods, reasons for missing observations, or outcome-specific numbers analyzed. The primary population is described as all treated participants, but there is no further accounting of inclusion in the endpoint analysis. It is not reported whether incomplete follow-up, withdrawals, or unavailable measurements occurred, or how these would have been handled.

Randomized allocation is recorded, but the record also characterizes the design as single-group and non-controlled. It does not define an intention-to-treat, per-protocol, or safety analysis population. Consequently, the reported enrollment cannot be assumed to be the denominator for each outcome, and the adverse-event denominators should not be extended to other analyses. Statistical methods, adjustment choices, and analysis populations are not reported in the registry record.

11. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 5% reporting threshold.

Most frequent serious adverse event terms

Most frequent non-serious adverse event terms

Serious events with the highest arm-level rate: endophthalmitis (25.0%).

The serious adverse-event entries are presented by dose group, with participants at risk and affected participants. The listing records 0 affected participants among 9 at risk at 0.04 mg, 0 among 7 at 0.15 mg, 0 among 6 at 0.4 mg, and 0 among 6 at 1.0 mg. At 2.0 mg, it records 1 affected participant among 4 at risk. These are group-specific descriptive counts, not comparisons adjusted for differences in group size or other characteristics.

The record names Endophthalmitis as a top serious event term and gives 25.0%. It does not provide additional event-level detail in the listed summary. The listed serious-event counts do not show whether an event was considered related to MP0112 or whether it was sight-threatening, both of which matter to the primary endpoint definition. The registry record does not report deaths. The safety listing does not include a 3.6 mg group, so no serious-event count for that dose is available in the record.

12. What the Result Does, and Does Not, Mean

The record establishes that MP0112 was studied as a single intravitreal injection across escalating dose levels in a phase I trial involving patients with wet age-related macular degeneration. It also establishes the prespecified description of the primary endpoint: a maximal tolerated dose based on specified severe or moderate ocular toxicity thresholds, with the selected dose set one level below the lower qualifying dose.

What the record does not establish is the numerical maximal tolerated dose. The result is not reported in the registry record, and the dose-specific event details needed to apply the decision rule are not available in the posted results. The serious adverse-event counts provide limited descriptive safety information, but they do not identify event relatedness or satisfy the endpoint’s full classification requirements. A serious-event count is not interchangeable with a count of moderate ocular drug-related toxicity.

The record also does not report numerical results for the named visual, anatomical, pharmacokinetic, or antibody outcomes. It therefore cannot support conclusions about the size, direction, or precision of any change in those measures. Since the trial is described as non-controlled, its listed observations cannot provide a treatment-versus-comparator estimate. The record does not permit a causal conclusion about whether the intervention produced any particular event or outcome.

These limits should not be interpreted as evidence that the study found no effect, no toxicity, or a particular dose. The absence of a posted result is not a null result. The status is terminated, but the reason is not reported in the registry record, so termination alone should not be used to infer the study’s findings or rationale.

In practical statistical terms, the available record supports description of the study design, endpoint definition, and specified safety counts. It does not support a precise dose-selection conclusion, efficacy estimate, controlled comparison, or inferential claim. Those would require outcome results and methods that are not reported in the registry record.

13. Why This Trial Matters Statistically

This trial illustrates a central issue in early-phase dose research: a dose-selection endpoint is only as interpretable as the event definitions and dose-specific data used to apply its rule. The registry gives a clear conceptual rule for maximal tolerated dose, including the role of severe sight-threatening events and moderate ocular toxicity. However, the numerical endpoint result and the details needed to evaluate those thresholds are not reported. A stated decision rule without its observed inputs cannot show how the decision was reached.

The study also highlights the distinction between describing safety and comparing safety. The posted serious-event entries allow readers to see the recorded counts in several dose groups, but a non-controlled design does not estimate how those counts differ from a comparator. Event seriousness, event relatedness, and whether an event meets the primary endpoint’s specific toxicity definition are separate considerations. Keeping these concepts distinct prevents a broad safety listing from being treated as a direct measurement of the primary endpoint.

Finally, the design labels require careful reading. The record says randomized allocation while also describing the study as non-controlled and single-group. Without further explanation, those labels do not define a comparative randomized trial. This is a useful reminder that registry metadata can contain different design descriptors, and that interpretation should rest on the available descriptions rather than assumed procedures.

The statistical importance of the record is therefore less about a reported numerical finding and more about the boundary between an endpoint’s definition and an interpretable result. Transparent reporting of dose-level observations, analysis populations, missing data, and uncertainty would be needed to assess the reliability and precision of a dose-selection conclusion.

14. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The primary limitation is that the registry record does not report the primary outcome result. Although the maximal tolerated dose definition is detailed, no selected dose or dose-specific qualifying toxicity findings are provided. The available serious-event counts do not identify the event attributes required by that definition, and moderate ocular drug-related toxicity counts are not reported.

The study is described as open-label, non-controlled, and single-group. There is no reported comparator for estimating relative safety or efficacy, and the allocation label of randomized is not explained in relation to the dose-escalation design. The registry record also does not state the escalation sequence or the procedures used to assign participants to dose levels.

Numerical results for the named secondary outcomes are not reported. The adverse-event listing does not include a group entry for 3.6 mg, and the reason is not stated. The record does not give outcome-specific analysis populations, missing-data methods, confidence intervals, or statistical analysis methods. It does not explain the relationship between the recorded enrollment and the number of participants contributing to each reported outcome.

The registry status is terminated, but the reason for termination is not reported in the registry record. No cause should be inferred from that status. These gaps restrict assessment of the endpoint, completeness of follow-up, precision, and potential bias. They do not establish that a particular result was absent in the study; they mean that it is not reported in the registry record.

15. Related Tutorials

16. Related Statistical Calculators

17. Sources

• ClinicalTrials.gov: Study of MP0112 Intravitreal Injection in Patients With Wet Age Related Macular Degeneration — NCT01086761.
• Registry record last updated 2014-05-12; status last verified 2014-04.
• Results first posted 2014-05-12.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

18. Record Summary

The record describes a phase I, open-label, non-controlled, multicentre dose-escalation study of MP0112 in patients with wet age-related macular degeneration. It lists a single intravitreal injection in the study eye at dose levels from 0.04 mg through 3.6 mg, recorded enrollment of 32, and status as terminated.

The primary endpoint was maximal tolerated dose following a single injection over 16 weeks, using a rule based on severe sight-threatening drug-related events or moderate ocular drug-related toxicity. The registry record does not report the endpoint result, a statistical analysis, or numerical findings for the named secondary outcomes. The safety listing gives serious-event counts for dose groups through 2.0 mg; the record does not provide a 3.6 mg safety-group entry or the reason the trial was terminated.